SEBI Reg. Investment Advisor

Download App

Help Center Subscribe

Recent:

Top Pharma Companies in India by Market Cap

BSE Sensex 76923.00
87.22 (0.11%)

Filter

Top Pharma Companies in India as on Jul-2026 | 5 Star Rated Stocks Undervalued Stocks Fair Valued Stocks Uptrend Stocks

Filter

	Company Name	DeciZen	Market cap (Rs. Cr.)	CMP (Change %)	Latest P/E	Latest P/BV	5Y Sales Gr.(%)	5Y Profit Gr.(%)
91	Procter & Gamble Health Ltd.	Q V+ PT	11,257 Small Cap	6,764 (-0.26%)	34.43	21.46	4.31	11.97	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
92	Rainbow Childrens Medicare Ltd.	Q V PT	15,076 Small Cap	1,474.10 (-0.69%)	60.3	8.95	20.26	35.07	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
93	RPG Life Sciences Ltd.	Q V+ PT	4,827 Small Cap	2,882.80 (-1.22%)	41.91	7.97	12.70	21.72	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
94	Rubicon Research Ltd.	Q V+ PT	25,860 Small Cap	1,563.90 (0.11%)	137.43	19.11	32.49	25.95	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
95	Sai Life Sciences Ltd.	Q V+ PT	27,347 Small Cap	1,291.45 (0.26%)	80.08	10.9	17.75	11.20	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
96	Sanofi Consumer Healthcare India Ltd.	Q V+ PT	10,773 Small Cap	4,692 (0.30%)	41.77	23.84	0.00	0.00	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
97	Sanofi India Ltd.	Q V PT	7,760 Small Cap	3,383.70 (0.43%)	25.05	9.95	-8.74	-7.50	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
98	Senores Pharmaceuticals Ltd.	Q V+ PT	6,500 Small Cap	1,317.55 (-6.66%)	349.68	8.67	0.00	0.00	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
99	Shalby Ltd.	Q V+ PT	1,783 Small Cap	161.50 (-2.15%)	15.79	1.43	12.52	25.39	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
100	Shilpa Medicare Ltd.	Q V+ PT	12,144 Small Cap	605 (-2.56%)	49.91	4.69	7.22	-12.54	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
101	Shree Ganesh Remedies Ltd.	Q V PT	822 Small Cap	636.35 (-0.63%)	46.26	5.04	13.20	20.49	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
102	Sigachi Industries Ltd.	Q V+ PT	991 Small Cap	25.43 (-1.93%)	N/A	2.08	24.05	7.49	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
103	SMS Pharmaceuticals Ltd.	Q V+ PT	3,662 Small Cap	382.60 (-2.15%)	41.8	4.55	13.70	14.47	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
104	Solara Active Pharma Sciences Ltd.	Q V PT	2,439 Small Cap	502 (-0.71%)	N/A	1.91	-0.58	-134.64	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
105	Strides Pharma Science Ltd.	Q V+ PT	9,623 Small Cap	1,055.20 (1.07%)	52.4	2.93	3.25	-0.75	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
106	Sun Pharma Advanced Research Company Ltd.	Q V+ PT	6,974 Small Cap	211 (-1.81%)	4.49	5.23	49.34	0.00	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
107	Sun Pharmaceutical Industries Ltd.	Q V+ PT	4,73,509 Large Cap	1,984.40 (0.55%)	41.25	5.67	11.78	14.41	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
108	Supriya Lifescience Ltd.	Q V+ PT	6,799 Small Cap	833.30 (-1.36%)	32.51	5.68	17.45	18.30	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
109	Suraksha Diagnostic Ltd.	Q V PT	1,300 Small Cap	249 (-0.28%)	40.4	5.31	9.86	-51.00	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
110	Suven Life Sciences Ltd.	Q V+ PT	8,807 Small Cap	297.85 (-4.44%)	N/A	5.02	-14.30	0.00	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
111	Syncom Formulations (India) Ltd.	Q V PT	1,240 Small Cap	13.08 (-0.83%)	16.31	3.01	17.63	21.67	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
112	Syngene International Ltd.	Q V+ PT	16,710 Small Cap	408.85 (-1.23%)	54.8	3.58	9.45	1.26	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
113	Tarsons Products Ltd.	Q V+ PT	1,707 Small Cap	310 (-3.40%)	75.35	2.53	12.30	-1.67	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
114	Themis Medicare Ltd.	Q V PT	995 Small Cap	107 (-0.97%)	N/A	3.71	15.00	7.68	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
115	Thyrocare Technologies Ltd.	Q V+ PT	9,287 Small Cap	592.20 (1.49%)	52.68	14.76	10.88	8.62	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
116	Torrent Pharmaceuticals Ltd.	Q V+ PT	1,90,832 Large Cap	4,921.50 (-1.90%)	88.21	22.69	11.80	13.74	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
117	Unichem Laboratories Ltd.	Q V PT	3,826 Small Cap	538.20 (-0.97%)	24.07	1.46	4.67	-173.72	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
118	Vijaya Diagnostic Centre Ltd.	Q V PT	13,894 Small Cap	1,347 (-0.14%)	80.32	14.52	15.00	18.43	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
119	Vimta Labs Ltd.	Q V+ PT	2,620 Small Cap	594.30 (1.35%)	32.89	5.57	14.27	28.52	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
120	Viyash Scientific Ltd.	Q V PT	11,352 Small Cap	255.65 (-1.62%)	64.03	4.2	20.23	2.33	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
Prev 1 2 3 4 5 Next

Screens:

AlphaCases Top Rated Stocks Best Nifty Stocks Best Nifty Next Stocks Best Nifty 500 Stocks Best SmallCap Stocks Top BFSI Stocks

Pharma - Today's Top Gainers

Company Name	CMP	Price Change(%)
Onesource Specialty	1,744.75	3.26%
Dr. Agarwals Health	487.60	2.53%
Metropolis Health.	590.30	2.17%
Laurus Labs	1,745.85	1.84%
Cipla	1,434.80	1.77%

Pharma - Today's Top Losers

Company Name	CMP	Price Change(%)
Acutaas Chemicals	3,121.05	-7.35%
Senores Pharmaceutic	1,317.55	-6.66%
Suven Life Sciences	297.85	-4.44%
Wanbury	318.55	-3.82%
Panacea Biotec	418.10	-3.51%

News about Top Pharma Companies in India

Jul, 2026

Senores Pharmaceutic - Quaterly Results

The turnover zoomed to Rs. 269.90 millions, up 67.33% for the June 2026 quarter as against Rs. 161.30 millions during the year-ago period.Net Profit of the company move down -61.85% to Rs. 10.30 millions from Rs. 27.00 millions in the same quarter last year.The company reported a degrowth in operating Profit to 72.20 millions from 72.30 millions.

(Rs. in Million)

	Quarter ended			Year to Date			Year ended
	202606	202506	% Var	202606	202506	% Var	202603	202503	% Var
Sales	269.90	161.30	67.33	269.90	161.30	67.33	1060.90	385.40	175.27
Other Income	95.50	120.80	-20.94	95.50	120.80	-20.94	663.50	219.90	201.73
PBIDT	72.20	72.30	-0.14	72.20	72.30	-0.14	476.70	147.10	224.07
Interest	22.20	17.60	26.14	22.20	17.60	26.14	69.80	65.20	7.06
PBDT	50.00	54.70	-8.59	50.00	54.70	-8.59	406.90	81.90	396.83
Depreciation	36.10	18.80	92.02	36.10	18.80	92.02	132.30	30.80	329.55
PBT	13.90	35.90	-61.28	13.90	35.90	-61.28	274.60	51.10	437.38
TAX	3.60	8.90	-59.55	3.60	8.90	-59.55	72.10	14.20	407.75
Deferred Tax	0.50	5.00	-90.00	0.50	5.00	-90.00	-12.40	-0.30	4033.33
PAT	10.30	27.00	-61.85	10.30	27.00	-61.85	202.50	36.90	448.78
Equity	460.54	460.54	0.00	460.54	460.54	0.00	460.50	460.50	0.00
PBIDTM(%)	26.75	44.82	-40.32	26.75	44.82	-40.32	44.93	38.17	17.73

Jul, 2026

SMS Pharmaceuticals informs about board meeting

SMS Pharmaceuticals has informed that the meeting of the Board of Directors of the Company is scheduled on 01/08/2026, inter alia, to consider and approve Un-audited Financial Results of the Company for the first quarter ended on June 30, 2026.

The above information is a part of company’s filings submitted to BSE.

Jul, 2026

Sun Pharmaceutical Industries informs about press release

Sun Pharmaceutical Industries has informed that it enclosed a copy of the press release titled ‘Sun Pharma Notes Organon Shareholder Approval for Proposed Acquisition,’ which shall be released after this intimation.

The above information is a part of company’s filings submitted to BSE.

Jul, 2026

Thyrocare Tech. - Quaterly Results

The sales figure stood at Rs. 2256.60 millions for the June 2026 quarter. The mentioned figure indicates a growth of about 26.14% as compared to Rs. 1788.90 millions during the year-ago period.Good Net Profit growth of 39.17% reported above the corresponding previous quarter figure of Rs. 360.50 millions to Rs. 501.70 millioins.OP of the company witnessed a marginal growth to 791.20 millions from 604.80 millions in the same quarter last year.

(Rs. in Million)

	Quarter ended			Year to Date			Year ended
	202606	202506	% Var	202606	202506	% Var	202603	202503	% Var
Sales	2256.60	1788.90	26.14	2256.60	1788.90	26.14	7742.70	6331.00	22.30
Other Income	35.10	39.60	-11.36	35.10	39.60	-11.36	133.90	133.40	0.37
PBIDT	791.20	604.80	30.82	791.20	604.80	30.82	2697.20	2003.60	34.62
Interest	12.60	6.20	103.23	12.60	6.20	103.23	21.80	26.30	-17.11
PBDT	778.60	598.60	30.07	778.60	598.60	30.07	2615.70	1977.30	32.29
Depreciation	112.30	89.50	25.47	112.30	89.50	25.47	511.70	465.20	10.00
PBT	666.30	509.10	30.88	666.30	509.10	30.88	2104.00	1512.10	39.14
TAX	164.60	148.60	10.77	164.60	148.60	10.77	615.90	554.30	11.11
Deferred Tax	0.00	0.00	0.00	0.00	0.00	0.00	43.00	76.60	-43.86
PAT	501.70	360.50	39.17	501.70	360.50	39.17	1488.10	957.80	55.37
Equity	1591.70	529.90	200.38	1591.70	529.90	200.38	1591.70	529.90	200.38
PBIDTM(%)	35.06	33.81	3.71	35.06	33.81	3.71	34.84	31.65	10.07

Jul, 2026

Solara Active Pharma - Quaterly Results

The revenue zoomed 19.57% to Rs. 3816.00 millions for the quarter ended June 2026 as compared to Rs. 3191.50 millions during the corresponding quarter last year.Profit for the quarter ended June 2026 rises by 61.35% to Rs. 169.90 millions from Rs. 105.30 millions.OP of the company witnessed a marginal growth to 639.30 millions from 580.10 millions in the same quarter last year.

(Rs. in Million)

	Quarter ended			Year to Date			Year ended
	202606	202506	% Var	202606	202506	% Var	202603	202503	% Var
Sales	3816.00	3191.50	19.57	3816.00	3191.50	19.57	13689.80	12837.60	6.64
Other Income	19.20	9.80	95.92	19.20	9.80	95.92	58.90	91.40	-35.56
PBIDT	639.30	580.10	10.21	639.30	580.10	10.21	1925.70	2129.80	-9.58
Interest	202.30	239.00	-15.36	202.30	239.00	-15.36	942.40	1148.10	-17.92
PBDT	437.00	341.10	28.11	437.00	341.10	28.11	924.40	981.70	-5.84
Depreciation	267.10	235.80	13.27	267.10	235.80	13.27	996.80	992.50	0.43
PBT	169.90	105.30	61.35	169.90	105.30	61.35	-72.40	-10.80	570.37
TAX	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Deferred Tax	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
PAT	169.90	105.30	61.35	169.90	105.30	61.35	-72.40	-10.80	570.37
Equity	480.60	443.40	8.39	480.60	443.40	8.39	445.10	402.50	10.58
PBIDTM(%)	16.75	18.18	-7.83	16.75	18.18	-7.83	14.07	16.59	-15.21

Jul, 2026

Rainbow Children’s Medicare informs about ESG rating

Pursuant to Regulation 30 of the SEBI Listing Regulations read with Schedule III thereto and the SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026, Rainbow Children’s Medicare has informed that CRISIL ESG Rating & Analytics (‘CRISIL ESG’) has on a voluntary basis assessed the overall Environmental, Social and Governance (ESG) and has assigned an ESG rating of 61 and a Core ESG rating of 73, based on disclosures for FY 2025-26, on July 22, 2026. The ESG rating of 61 reflects an improvement from ‘Adequate’ to ‘Strong’ ESG rating assigned to the Company for FY 2024-25 and FY 2023-24. The Company has not engaged CRISIL ESG for ESG Ratings. CRISIL ESG has independently prepared the report based on data pertaining to FY 2025-26 for the Company available in public domain.

The above information is a part of company’s filings submitted to BSE.

Top 10 Publicly Listed pharmaceutical stocks in India by Market Capitalization as of 2026.

Rank	Company	Market Capitalization 2026 (INR crores)
1	3B Blackbio Dx Ltd.	1,112 Crore
2	Aarti Drugs Ltd.	3,752 Crore
3	Aarti Pharmalabs Ltd.	6,217 Crore
4	Abbott India Ltd.	59,102 Crore
5	Acutaas Chemicals Ltd.	27,579 Crore
6	Advanced Enzyme Technologies Ltd.	3,555 Crore
7	Ajanta Pharma Ltd.	42,278 Crore
8	Akums Drugs & Pharmaceuticals Ltd.	10,638 Crore
9	Alembic Pharmaceuticals Ltd.	16,009 Crore
10	Alivus Life Sciences Ltd.	13,876 Crore

Do you know? Asking 3 Right Questions minimizes the RISK of Stock Investing To Know

Right Stock | Right Price | Right Allocation

Find best stocks to buy now Find best pharma stocks to buy now

Top 15 Pharma Stocks by Revenue Growth

Top Pharma Companies Source: NSE Indices

You can use different criterias to arrive at the list of best stocks in the Nifty Pharma company index. You can use return ratios like ROCE or ROE, that will help you choose companies with profitable growth.

Based on ROE, the best stocks in the Nifty Pharma companies index are:

Company Name	Is it a Right Stock ?	CMP	Market Cap(Cr.)	P/E	P/BV	EV/EBITDA	ROE
Abbott India Ltd. (M)	Very Good	27,893	59,102	38.08	12.45	26.07	34.24
Torrent Pharmaceuticals Ltd. (L)	Very Good	4,922	1,90,832	88.21	22.69	45.79	29.04
Lupin Ltd. (M)	Somewhat Good	2,405	1,10,189	20.66	4.92	11.95	26.43
Ajanta Pharma Ltd. (M)	Very Good	3,358	42,278	40.04	9.35	27.05	25.35
Alkem Laboratories Ltd. (M)	Very Good	5,631	67,124	30.72	4.80	22.28	17.86

Based on the past year's gain, the best performing stocks are:

Company Name	Is it a Right Stock ?	CMP	Market Cap(Cr.)	Yearly gain (%)
Laurus Labs Ltd. (M)	Very Good	1,746	92,623	105
Sai Life Sciences Ltd. (S)	Very Good	1,291	27,347	53.73
Torrent Pharmaceuticals Ltd. (L)	Very Good	4,922	1,90,832	39.27
Aurobindo Pharma Ltd. (M)	Very Good	1,553	89,115	38.01
Lupin Ltd. (M)	Somewhat Good	2,405	1,10,189	23.52
				View More

Stocks with the highest revenue growth in the past 5 years is:

Company Name	Is it a Right Stock ?	CMP	Market Cap(Cr.)	P/E	P/BV	EV/EBITDA	5Y Sales Growth (%)
Sai Life Sciences Ltd. (S)	Very Good	1,291	27,347	80.08	10.90	42.11	17.75
Ajanta Pharma Ltd. (M)	Very Good	3,358	42,278	40.04	9.35	27.05	13.54
Mankind Pharma Ltd. (M)	Very Good	2,587	1,05,357	51.71	6.44	32.38	13.54
Zydus Lifesciences Ltd. (M)	Very Good	1,109	1,10,523	21.93	4.25	13.45	13.52
Lupin Ltd. (M)	Somewhat Good	2,405	1,10,189	20.66	4.92	11.95	13.02

Stocks with high profit growth often witness their stock prices gaining, irrespective of the market movements.

Stocks with the highest profit growth in the past 5 years is:

Company Name	Is it a Right Stock ?	CMP	Market Cap(Cr.)	P/E	P/BV	EV/EBITDA	5Y Profit Growth (%)
Lupin Ltd. (M)	Somewhat Good	2,405	1,10,189	20.66	4.92	11.95	32.37
Abbott India Ltd. (M)	Very Good	27,893	59,102	38.08	12.45	26.07	17.33
Dr. Reddys Laboratories Ltd. (M)	Very Good	1,146	96,063	29.81	2.52	15.31	15.75
Zydus Lifesciences Ltd. (M)	Very Good	1,109	1,10,523	21.93	4.25	13.45	14.72
Sun Pharmaceutical Industries Ltd. (L)	Very Good	1,984	4,73,509	41.25	5.67	23.65	14.41

You have 7 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login | Register Now

Create stable, long-term investment portfolio with strong, consistent stocks.

Start Research-backed Investing ...Now. Subscribe to Sapphire

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Fiduciary-first advisory model.
As SEBI-registered IAs, we are legally and ethically bound to act in the best interests of our clients. We do not sell or distribute any financial products. This ensures our guidance is 100% unbiased and conflict-free.
Deep fundamental research + robust valuation discipline.
Built on more than 15 years of equity research, our framework combines quality assessment, intrinsic value estimation, and a sensible margin-of-safety approach.
Process—not predictions.
We don’t rely on guesswork or market timing. Instead, we focus on asset allocation, risk management, and long-term compounding.
Technology + Human Intelligence.
We believe a combination of both is essential for investing success. We constantly innovate and upgrade in-house tools, financial X-rays, and portfolio analytics so that our team of analysts and advisors are equipped with the best.
Partner with Clients.
We follow a DIWM (Do-It-With-Me) approach where we partner clients in setting goals, financial planning, educating on our investing process and share decision-enabling resources transparently with our clients who retain control on execution.

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

Investing in stocks, mutual funds, debt, and gold
Quality-at-Reasonable-Price way of investing in stocks
Constructing Direct Stock Portfolios with Core, Booster, and Amplifier stocks
A Mutual Fund Portfolio that delivers consistent out-performance and meaningful diversification (low overlap)
Periodic review and rebalancing
Clear Buy-Sell-Hold, and Position-sizing frameworks

Name of the IA registered with SEBI:	The Alchemists Ark Pvt. Ltd.
Logo:
Trade/Brand Name of IA:	MoneyWorks4Me Investment Advisers
Brand Logo:
SEBI Registration Number:	INA000013323 Validity – May 16, 2019 – Perpetual
Registration:	Non-Individual
BSE Enlistment No:	1187
Address:	B-101, Signet Corner Building, Balewadi Phata, Baner, Pune, Maharashtra 411045
Compliance officer Details:	Name: Shrikant Jagtap Email: shrikant.jagtap@moneyworks4me.com Telephone: +919860359463 Address: Same as IA
Grievance Officer Details:	Name: Mukta Vaze Email: mukta.vaze@moneyworks4me.com Telephone: +91 98609 19463 Address: Same as IA
Principal Officer Details:	Name: Atharva Bhide Email: atharva.bhide@moneyworks4me.com Telephone: +91 91758 99463 Address: Same as IA
Standard Warning:	Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Disclaimer:	Registration granted by SEBI, enlistment with exchange and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Top Pharma Companies in India by Market Cap

News about Top Pharma Companies in India

Senores Pharmaceutic - Quaterly Results

SMS Pharmaceuticals informs about board meeting

Sun Pharmaceutical Industries informs about press release

Thyrocare Tech. - Quaterly Results

Solara Active Pharma - Quaterly Results

Rainbow Children’s Medicare informs about ESG rating

Publicly traded pharmaceuticals

Top 10 Publicly Listed pharmaceutical stocks in India by Market Capitalization as of 2026.

Top 15 Pharma Stocks by Revenue Growth

Top Pharma Companies Source: NSE Indices

How to select the top Nifty Pharma stocks based on RoE?

What are the best-performing stocks in the Nifty Pharma index?

Which Nifty Pharma stocks have the highest revenue growth in the past five years?

Which Nifty Pharma stocks had the highest profit growth in the past five years ?

Create stable, long-term investment portfolio with strong, consistent stocks.

About MoneyWorks4Me

Our Vision

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.